Heron Therapeutics enters supply agreement with Patheon and Thermo Fisher
Prestige Consumer Healthcare Inc. stock reached a new 52-week low, closing at 64.83 USD. According to InvestingPro data, the company maintains strong fundamentals with a healthy current ratio of 4.2 and is currently showing signs of being slightly undervalued. This development marks a significant point for the company, as its stock has experienced a notable decline, with a sharp 8.29% drop just in the past week. The drop to this 52-week low reflects ongoing market challenges and investor sentiment towards the company. InvestingPro analysis reveals the stock’s RSI is indicating oversold conditions, with 11 additional real-time ProTips available for subscribers. Despite the decrease, Prestige Consumer Healthcare continues to navigate the evolving landscape of the healthcare industry, aiming to stabilize and potentially rebound in the coming months. With a market capitalization of $3.25 billion and a P/E ratio of 17.64, detailed valuation metrics and comprehensive analysis are available in the Pro Research Report on InvestingPro.
In other recent news, Prestige Brands reported a 6.6% year-over-year decline in sales for the first quarter of fiscal 2026, totaling $249.5 million. This figure fell short of both Canaccord Genuity’s estimate of $258.8 million and the company’s own guidance range. Additionally, adjusted earnings per share were reported at $0.95, missing estimates of $1.00. Following these results, Canaccord Genuity lowered its price target for Prestige Brands to $100, although it maintained a Buy rating. Meanwhile, Jefferies raised its price target for the company to $85 from $81, maintaining a Hold rating, citing the company’s strong performance and diverse product portfolio as key strengths.
In other developments, Medtech Products Inc., a subsidiary of Prestige Consumer Healthcare Inc., announced a recall of five lots of Little Remedies Honey Cough Syrup due to Bacillus cereus contamination. The recall affects products distributed nationwide between December 2022 and June 2025. The affected lots include those with expiration dates ranging from November 2025 to December 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.